{"disease":{"id":"advanced-hepatocellular-carcinoma-hcc","name":"advanced hepatocellular carcinoma hcc"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04523493","title":"Phase III Study of Toripalimab（JS001） Combined With Lenvatinib for Advanced HCC","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":530,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT05824975","title":"A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":358,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT04723004","title":"Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":326,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT03236636","title":"The Phase III Study of Icaritin Versus HUACHANSU PIAN in Hepatocellular Carcinoma Subjects","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":312,"lead_sponsor_name":"Beijing Shenogen Biomedical Co., Ltd","has_results":false},{"nct_id":"NCT07583316","title":"A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":192,"lead_sponsor_name":"Corregene Biotechnology Co., Ltd","has_results":false},{"nct_id":"NCT07197554","title":"A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":171,"lead_sponsor_name":"SEED Therapeutics, Inc.","has_results":false},{"nct_id":"NCT07147101","title":"Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":150,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT06828380","title":"A Study Comparing Immunotherapy Alone Versus Immunotherapy Combined With Radiotherapy in Patients With Hepatocellular Carcinoma (HCC) With Vascular Invasion","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":128,"lead_sponsor_name":"National Cancer Center, Korea","has_results":false},{"nct_id":"NCT07282509","title":"Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of Advanced Liver Cancer","phase":"PHASE1, PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":116,"lead_sponsor_name":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","has_results":false},{"nct_id":"NCT04212221","title":"MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in Advanced Liver Cancer Patients","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":89,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":true},{"nct_id":"NCT06749678","title":"Effect of Prehabilitation During the Conversion Therapy on Postoperative Outcomes in Unresectable Hepatocellular Carcinoma","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":84,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT06737913","title":"HAI or IV of Adebrelimab, Combined With Bevacizumab and HAI of FOLFOX for Advanced Unresectable Hepatocellular Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07321067","title":"Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":75,"lead_sponsor_name":"Ahmed Karam Helmy","has_results":false},{"nct_id":"NCT06971237","title":"SIRT and Peri-immunotherapy : a New Concept","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT04605796","title":"A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT06995105","title":"Personalized Tumor Neoantigen mRNA Therapy for Advanced Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT06902389","title":"A Clinical Study of Multi-target Hi-TCR-T Cells in the Treatment of Advanced Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Eastern Hepatobiliary Surgery Hospital","has_results":false},{"nct_id":"NCT07500220","title":"Dual-Target GPC3/B7-H3 CAR-NK Cells for Advanced HCC","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Beijing Biotech","has_results":false},{"nct_id":"NCT01356628","title":"A Clinical Research Study to Determine Whether PD 0332991 May Be Effective in Treating Patients With Liver Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":23,"lead_sponsor_name":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","has_results":true},{"nct_id":"NCT01101906","title":"A Randomized, Placebo-controlled, Double-blind Phase 2 Study With OSI-906 in Patients With Advanced HCC","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":23,"lead_sponsor_name":"Astellas Pharma Inc","has_results":false},{"nct_id":"NCT07123545","title":"Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":20,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT07493044","title":"An Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Guangzhou FineImmune Biotechnology Co., LTD.","has_results":false},{"nct_id":"NCT02906397","title":"Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Advanced Hepatocellular Carcinoma (HCC)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":15,"lead_sponsor_name":"Abramson Cancer Center at Penn Medicine","has_results":false},{"nct_id":"NCT07039201","title":"A Study to Evaluate CG-102-12C in Glypican-3 (GPC3) Positive Advanced Hepatocellular Carcinoma (HCC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":12,"lead_sponsor_name":"Zhejiang University","has_results":false},{"nct_id":"NCT05375604","title":"A Study of exoASO-STAT6 (CDK-004) in Patients With Advanced Hepatocellular Carcinoma (HCC) and Patients With Liver Metastases From EIther Primary Gastric Cancer or Colorectal Cancer (CRC)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":9,"lead_sponsor_name":"Codiak BioSciences","has_results":false},{"nct_id":"NCT04985136","title":"A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":1,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false}],"total":26},"guidelines":[],"source":"Drug Landscape verified database"}